BioWorld

March 27, 2009

View Archived Issues

Reata Completes $32M Financing to Fund Studies of CKD Drug

Reata Pharmaceuticals Inc. has the cash to fund a mid-stage trial of its lead drug candidate for advanced chronic kidney disease, now that the Irving, Texas-based company has completed a $32 million Series F financing. (BioWorld Today) Read More

Tricky Endpoints Doom Neurocrine Pain Trial

Read More

New Route for Toxic Asset's Exit Strategy is Discovered

Read More

Tackling Neurodegenerative Space, Neuraltus Raises $17M

Read More

Avigen Board Opts to Liquidate, Pending Shareholder Meeting

Read More

Other News To Note

Read More

Clinic Roundup

Read More